Literature DB >> 12672614

Synthesis, preformulation and liposomal formulation of cholesteryl carborane esters with various fatty chains.

Fars Alanazi1, Hengguang Li, David S Halpern, Svein Øie, D Robert Lu.   

Abstract

The elevated expression of LDL receptor on tumor cells provides one attractive approach for targeted drug delivery to tumor cells. Suitable antitumor compounds, however, need to be synthesized and developed which mimic the native cholesteryl esters (as major constituent of LDL) in chemical structure for targeted delivery to tumor cells through the over-expressed LDL receptors. In the present study, new antitumor compounds were designed containing cholesterol, fatty chain and carborane which is used as the antitumor unit. Three new compounds were synthesized with a three-step reaction scheme. Similar to the native cholesteryl esters, these compounds are extremely hydrophobic and, before any further biological studies, suitable liposomal formulations for these new compounds are required. Various liposomal formulations as well as the preformulation characterization of these new compounds were thus examined. The incorporation efficiency of the compounds in liposomes was found to vary significantly depending on the type of fatty chain attached and the ratio of cholesterol:phospholipid used as the excipients of liposomal formulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672614     DOI: 10.1016/s0378-5173(03)00088-7

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Synthesis of α-carboranyl-α-acyloxy-amides as potential BNCT agents.

Authors:  Subash C Jonnalagadda; Jonathan S Cruz; Ryan J Connell; Patricia M Scott; Venkatram R Mereddy
Journal:  Tetrahedron Lett       Date:  2009-07-29       Impact factor: 2.415

Review 2.  Low density lipoprotein bionanoparticles: From cholesterol transport to delivery of anti-cancer drugs.

Authors:  Gamaleldin I Harisa; Fars K Alanazi
Journal:  Saudi Pharm J       Date:  2013-12-22       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.